Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
暂无分享,去创建一个
J. Vose | C. Flowers | S. O'brien | J. Burger | M. Lunning | W. Wierda | T. Siddiqi | L. Nastoupil | N. Fowler | Jonathon B. Cohen | M. Schreeder | P. Sportelli | M. Purdom | M. S. Weiss | J. Cohen | H. Miskin | M. Weiss